Hello again everyone!
After scanning and probing these OTC markets for the next big possible winner, something just jumped right out and licked me right in the face!
Oh, come on! ……Who doesn’t let their pet lick them in the face?
That’s right! The next potential big play to come our way is the very pet friendly, PTLF.
PTLF (Petlife Pharmaceuticals, Inc.)
Like you’ve just heard, PTLF is the pet friendly pharmaceutical company that understands how important your pet is to your family.
According to the American Pet Products Association, Americans spent more than $50 billion on their beloved cats, dogs, and other animal companions!
Pet ownership in the U.S. has more than tripled from the 1970s, when approximately 67 million households had pets, to recently when there were 164 million owned pets.
In other words, 62% of American households included at least one pet.
The National Cancer Institute (NCI) reports that in the US alone, nearly 6 million dogs and 6.5 million cats are diagnosed with cancer annually.
Based on the fact that not only has pet ownership exploded over the last 40+ years, in addition to millions of dollars spent to enhance pet lifestyle, its become very evident that pets are seen as family members and as such, owners will spare no expense to prolong life.
PTLF has a corner on the industry through its exclusive patent rights to expand on and increase the overall development of this new cancer treatment specific to pets…a multi-billion dollar industry and growing.
Petlife Pharmaceuticals, Inc., or PTLF, has identified the next generation of cancer medication that may not only be able to treat cancer but also to prevent it…with a little twist.
Read this profile and check it out ASAP because the window of opportunity won’t stay open for long.
Escozine™, a drug that’s been prescribed as a cancer medication in more than 40 countries including the US, has been marketed as a dietary supplement for humans and is actually derived from Caribbean blue scorpion venom!
What PTLF has done is utilize its application to man’s best friends…pets.
PTLF has found that dogs and cats are quite similar at the molecular level and the growing body of new preclinical research (UCSD) establishing the effectiveness of Escozine™ has been found that it can be applied for animals.
As stated above and on the company website, (which will be provided in the newsletter) PTLF has an expanding operation and exclusive patent rights to a cancer fighting and potential cancer prevention drug.
Why is this so significant? Why could it spell big things for this growing company? ……..Come on, I think you already know!
BUSINESS SUMMARY
(PTLF – PetLife Pharmaceuticals Inc. / PPS. - .40)
PetLife Pharmaceuticals Inc. has licensed the worldwide rights to formulate, package and market a new product line, “Escozine for Pets™.
The Company’s products have shown potential to prevent and treat cancer, and to dramatically improve the quality of life, and extend the longevity, of pets with cancer -- without the harmful side effects of conventional chemotherapy.
PetLife Pharmaceuticals Inc. has also studied and plans to introduce an Escozine™ product line for livestock, which suffer from high rates of cancer at a cost of billions to the industry. As of the end of October, the Company announced that it would be starting pre-clinical trials with the most common canine cancer tumor cell lines.
Furthermore the results from these trials were planned for release sometime in December…guess what month it is…
The Patent & Product Application
According to PetLife Pharmaceuticals Inc., basic claims are consistent with US Patent # US 8097284 B2. However, the Patent Continuation for “Polarized Dilute Blue Scorpion Venom solution for Veterinary Use” includes additional information: it expands the description of the molecular excitement of vibration leading to absorption of the quanta of energy for potentiation of the blue scorpion extract which increases its therapeutic effectiveness.
Escozine™ was originally developed and commercialized by Medolife Corp. in 2007. Medolife currently holds the exclusive patent license for the human applications, (United States patent # 8,097,284 B2) of the bioactive peptide and polarization technology used to make the Polarized Dilute Blue Scorpion Venom.
In 2014, the patent holder, Arthur Grant Mikaelian, granted an exclusive global license for production, marketing and sales to (PTLF), for all veterinary applications of Escozine for Pets™, including the nutraceutical and future FDA approved versions.
PetLife Pharmaceuticals Inc. is working on different delivery methods including a patch, enema treatments, and oral dosage.
These products will have the effect of prolonging pets’ lives when taken consistently. Part of PTLF sales and marketing framework is to not only sell the products to companion animals post cancer diagnosis, but to educate owners on cancer and autoimmune prevention.
MARKET OUTLOOK
The global veterinary industry encompasses various veterinary health products such as biologicals, medicated feed additives and veterinary pharmaceuticals. Animal health product ranges are becoming more extensive, now including metabolic drugs, anti-infectives, reproductive aids, feed additives, vaccines, imaging diagnostics, topical solutions and parasite controls, reports TriMark Publications. Products used to treat chronic illnesses including cancer, cardiovascular disease and osteoarthritis, also fall into this market category.
Pet owners are spending more and more on caring for their pets’ health. In the US, consumer spending on domestic animals is forecast to reach $33 billion in 2014, according to research from Freedonia. Pet health product demand at the manufacturer level is expected to rise almost 6% yearly to reach $5.5 billion in 2014.
Market growth will be fuelled by an expanding pet population and changing attitudes that see owners treat their pets as companions or family members. Due to this new trend, the pet health market has fared the economic recession well, with owners reluctant to cut back on pet spending.
The bulk of the animal health market is comprised of products that aim to increase animal longevity and improve quality of life, such as vaccines, medical feed additives, antifungals, anthelmintics and parasiticides. Koncept Analytics breaks down the market in terms of categories based on animal species. The market can be broken down according to products used, with medicinal feed additives, biologics and parasiticides representing the three leading market segments. Pharmaceuticals represent the leading category and encompass anti-infectives, parasiticides and other drugs.
Products emphasizing prevention continue to record strong market growth, including parasiticides and dietary supplements. Prior to 2010 pharmaceuticals replaced parasiticides as the leading market segment. Due to the array of medical conditions affecting domestic animals, rising veterinary costs and greater awareness, many owners are opting to cover their pets with pet insurance policies. Owners are therefore in a better position to pay for costly veterinary procedures.
INVESTOR HIGHLIGHTS
PTLF has licensed the worldwide rights to formulate, package and market a new product line, “Escozine for Pets™.
Consumer spending on domestic companion animals is expected to reach over $50 billion in 2014 with over $13 billion being spent on over the counter medications, according to the American Pet Products Association (2014).
62% of American households include at least one pet.
PTLF has received a financing offer from an international investment fund for a $2.5 million to $5 million financing that will be used to finance the commercial launch of PetLife's nutraceutical products, and to commence the FDA Abbreviated New Drug Application (ANDA) approval process for three prescription drug versions of Escozine for Pets™.
This industry has seen an incredible amount of growth over the last few decades. Pets are becoming more a part of the family structure and owners are spending more and more per year not only on accessories but also on the healthcare aspect.
PTLF recognizes increasing spending on animals continues to increase and due to the nature of the limited amount of actual cancer treatments on the market that are specific to pets, PTLF can capitalize on the potential opportunity. The high likelihood of further developments and increasing effectiveness in the veterinary medical community as an effective therapeutic treatment will only foster more growth in this industry. PTLF seems determined and well on their way to capitalizing on such an emerging market.
The time to get involved is before other companies identify other ways to implement cancer treatment within this multi-billion dollar industry, not after.
So now’s the time to get moving and start your own due diligence!
The OTC markets can be very quick and volatile so it is important to always use caution when following a stock and never risk any more than you can afford to lose.
